IV Medications for Acute Vertigo
For acute peripheral vertigo in the emergency department, intravenous promethazine 25 mg is the most effective option, demonstrating superior vertigo reduction compared to lorazepam and dimenhydrinate, with significant improvement in both vertigo intensity and associated nausea.
Primary Recommendation
Promethazine 25 mg IV is the first-line IV medication for acute peripheral vertigo based on the highest quality comparative evidence 1. This medication achieved a 46.5 mm reduction in vertigo intensity on visual analog scale at 2 hours, compared to only 25.7 mm with lorazepam (p<0.001). Additionally, promethazine provided superior nausea control (28.7 mm vs 22.8 mm reduction, p=0.002) 1.
Alternative IV Options (in order of preference)
Dimenhydrinate 50 mg IV: Second-line option if promethazine is unavailable. Demonstrated better efficacy than lorazepam with 1.5 units greater reduction in vertigo with ambulation at 2 hours, better ambulation ability (p<0.001), and significantly less sedation 2.
Lorazepam 2 mg IV: Third-line option. While less effective for vertigo reduction, it may have a role in managing psychological anxiety secondary to vertigo 3. However, it causes significantly more lethargy (14.1% vs 4.3% with promethazine, p=0.013) 1.
Critical Guideline Context
Vestibular suppressants should NOT be used routinely for vertigo management 3. The 2017 AAO-HNS guideline explicitly states these medications are only indicated for:
- Short-term management of severe autonomic symptoms (nausea/vomiting) in acutely symptomatic patients
- Patients who refuse definitive therapy (e.g., canalith repositioning procedures for BPPV)
- Prophylaxis before planned repositioning maneuvers in patients with prior severe nausea/vomiting 3
Important Caveats and Pitfalls
Do not use IV medications as primary treatment for BPPV: Physical maneuvers (Epley, Semont) are definitive treatment. Patients who underwent Epley maneuver alone recovered faster than those who received concurrent vestibular suppressants 3.
Avoid benzodiazepines in elderly patients: All vestibular suppressants, especially benzodiazepines, are independent risk factors for falls, cognitive deficits, and interference with driving. Risk increases with polypharmacy 3.
Reassess within 1 month: Patients with persistent symptoms after initial treatment require reevaluation to identify those who may benefit from vestibular rehabilitation or alternative diagnoses 3.
Side Effect Profile
- Promethazine: Drowsiness (10.8%), less lethargy than lorazepam 1
- Lorazepam: Lethargy (14.1%), increased drowsiness (1.8 units greater than dimenhydrinate) 1, 2
- Dimenhydrinate: Less sedating than lorazepam, better functional outcomes 2
Additional Acute Management Considerations
For severe acute spontaneous vertigo, older literature suggests combining antiemetics with vestibular damage-reducing agents such as magnesium sulfate IV (2 ampoules in 500cc physiological solution twice daily) or piracetam IV 4. However, prioritize the evidence-based promethazine regimen as it has the strongest comparative trial data 1.
Position the patient on their healthy side with head and trunk elevated 20 degrees in a quiet but not darkened room during acute symptoms 4.